Autologous stem cell therapy - Lifecells LLC

Drug Profile

Autologous stem cell therapy - Lifecells LLC

Alternative Names: ASCT01

Latest Information Update: 02 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lifecells LLC
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peripheral ischaemia

Most Recent Events

  • 01 Mar 2016 Lifecells completes a phase I/II trial in Peripheral ischaemia in USA (Intra-arterial, IM) (NCT01867190)
  • 11 Dec 2015 Phase I/II development is ongoing in USA (IM & Intra-arterial)
  • 31 May 2013 Phase-I/II clinical trials in Peripheral ischaemia in USA (IM) (NCT01867190)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top